Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 11/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266167 | 0.91 | NOS2 (0.38) | SIRT2SIRT1SIRT3NOS2CD38 | |
| SCHEMBL1728910 | 0.85 | CHRM4 (0.44) | SIRT2SIRT1SIRT3CYP2C9NOS2 | |
| SCHEMBL3270012 | 0.79 | KDM4E (0.49) | — | |
| SCHEMBL3265682 | 0.77 | CHRM4 (0.58) | SIRT2SIRT1SIRT3CHRM4 | |
| SCHEMBL1728003 | 0.76 | CD38 (0.43) | NOS2CD38EGLN2P4HTMCHEK1 | |
| SCHEMBL1729289 | 0.76 | P4HTM (0.38) | SIRT2SIRT1SIRT3CYP2C9NOS2 | |
| SCHEMBL3265698 | 0.76 | CHRM4 (0.48) | SIRT2SIRT1SIRT3CHRM4 | |
| SCHEMBL3265663 | 0.76 | CHRM4 (0.44) | SIRT2SIRT1SIRT3CHRM4 | |
| SCHEMBL3268956 | 0.75 | TPSAB1 (0.41) | SIRT2SIRT1SIRT3CYP2C9CHRM4 | |
| SCHEMBL1729376 | 0.74 | P4HTM (0.39) | CYP2C9NOS2EGLN2P4HTMCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SIRT2 268/4885SIRT1 987/4885SIRT3 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.